Related EU-projects

FP7

PERSIST
Title: Persisting Transgenesis
Research area: FP7-HEALTH- 01/01/2009 Development of emerging gene therapy tools and technologies for clinical application.
Project start date: [2009-01-01]

CELL-PID
Title: Advanced cell-based Therapies for the treatment of Primary ImmunoDeficiency
Research area: FP7-HEALTH-2010-1.4-1 Translational research on cell-based immunotherapy.
Project start date: [2010-11-01]

RNAI IN HSC VIA NP
Title: Delivery of siRNAs to hematopoietic stem cells using nanoparticles
Research area: FP7-PEOPLE-2009-RG Marie Curie Action: "Reintegration Grants".
Project start date: [2010-01-01]

TREATPD
Title: Cell and gene therapy based approaches for treatment of Parkinson's disease: From models to clinics
Research area: ERC-SG-LS5 ERC Starting Grant - Neurosciences and neural disorders.
Project start date: [2009-11-01]

INDUVIR
Title: Improved gene transfer system to iPS cells in mouse
Research area: FP7-PEOPLE-2009-RG Marie Curie Action: "Reintegration Grants".
Project start date: [2009-10-01]

IRLVGTMND
Title: Improved retrograde lentiviral vectors for gene therapy in motor neuron diseases
Research area: ERC-AG-LS7 ERC Advanced Grant - Diagnostic tools, therapies and public health.
Project start date: [2009-04-01]

NEUGENE
Title: Advanced gene therapy tools for treatment of CNS-specific disorders
Research area: HEALTH-2007-1.4-5 Gene therapy tools targeting the central nervous system.
Project start date: [2008-10-01]

EUCLYD
Title: A European consortium for Lysosomal disorders
Research area: HEALTH-2007-2.4.4-1 Natural course and pathophysiology of rare diseases.
Project start date: [2008-05-01]

EATRIS
Title: The European advanced translational research infrastructure in medicine
Research area: INFRA-2007-2.2-01 Preparatory phase for the projects in the 2006 ESFRI Roadmap.
Project start date: [2008-01-01]


FP6

Concerted Safety & Efficiency Evaluation of Retroviral Transgenesis in Gene Therapy of Inherited Diseases

Activity area acronym: FP6-LIFESCIHEALTH
Project Reference: 5242
Project Acronym: CONSERT
Action Line: LSH-2003-1.2.4-1 Improved gene delivery systems for the therapy of severe acquired diseases,LSH-2003-1.2.4-2 Gene therapy of inherited diseases
Action Line (spf): FP6-LIFESCIHEALTH LSH-2003-1.2.4-1 Improved gene delivery systems for the therapy of severe acquired diseases,LSH-2003-1.2.4-2 Gene therapy of inherited diseases

European network for the advancement of clinical gene transfer and therapy

Activity area acronym: FP6-LIFESCIHEALTH
Project Reference: 18933
Project Acronym: CLINIGENE
Action Line: LSH-2004-1.2.4-3 Quality and safety standards for clinical gene transfer
Action Line (spf): FP6-LIFESCIHEALTH LSH-2004-1.2.4-3 Quality and safety standards for clinical gene transfer

Development and application of transposons and site-specific integration technologies as non-viral gene delivery methods for ex vivo gene-based therapies

Activity area acronym: FP6-LIFESCIHEALTH
Project Reference: 18961
Project Acronym: INTHER
Action Line: LSH-2004-1.2.4-4 Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of SMEs)
Action Line (spf): FP6-LIFESCIHEALTH LSH-2004-1.2.4-4 Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of SMEs)

Combined isolation and stable non-viral transfection of hematopoietic cells- a novel platform technology for ex vivo hematopoietic stem cell gene therapy

Activity area acronym: FP6-LIFESCIHEALTH
Project Reference: 19038
Project Acronym: MAGSELECTOFECTION
Action Line: LSH-2004-1.2.4-4 Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of SMEs)
Action Line (spf): FP6-LIFESCIHEALTH LSH-2004-1.2.4-4 Development of new non-viral gene delivery technologies for ex vivo gene-based therapies (especially orientated towards involvement of SMEs)